Chiesi Farmaceutici

Chiesi explores the impact of climate change on people living with respiratory conditions in the series "The Climate and Us"

Retrieved on: 
Tuesday, December 5, 2023
Carbon, Climate change, Policy, Air pollution, Investment, Asthma, Patient, Climate, PMDI, Health, BBC, Health care, Quality of life, Environment, Habit, Renewable energy, Chiesi Farmaceutici

By doing so, Chiesi is committed to making a positive impact that will resonate with all stakeholders involved, prioritizing the interest of people living with respiratory conditions.

Key Points: 
  • By doing so, Chiesi is committed to making a positive impact that will resonate with all stakeholders involved, prioritizing the interest of people living with respiratory conditions.
  • Giuseppe Accogli, CEO of Chiesi Group, commented "As a Sustainable Company, we need to be transparent about the impact we have.
  • By focusing on the interconnection between patients and Planet health, Chiesi continues to drive positive change in the healthcare industry.
  • The "Climate and Us" series is available on the hub-site www.theclimateandus.com and the "How redesigning inhalers could reduce their environmental impact" episode, sponsored by Chiesi, is available by clicking here .

Chiesi explores the impact of climate change on people living with respiratory conditions in the series "The Climate and Us"

Retrieved on: 
Tuesday, December 5, 2023
Carbon, Climate change, Policy, Air pollution, Investment, Asthma, Patient, Climate, PMDI, Health, BBC, Health care, Quality of life, Environment, Habit, Renewable energy, Chiesi Farmaceutici

By doing so, Chiesi is committed to making a positive impact that will resonate with all stakeholders involved, prioritizing the interest of people living with respiratory conditions.

Key Points: 
  • By doing so, Chiesi is committed to making a positive impact that will resonate with all stakeholders involved, prioritizing the interest of people living with respiratory conditions.
  • Giuseppe Accogli, CEO of Chiesi Group, commented "As a Sustainable Company, we need to be transparent about the impact we have.
  • By focusing on the interconnection between patients and Planet health, Chiesi continues to drive positive change in the healthcare industry.
  • The "Climate and Us" series is available on the hub-site www.theclimateandus.com and the "How redesigning inhalers could reduce their environmental impact" episode, sponsored by Chiesi, is available by clicking here .

Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Retrieved on: 
Monday, November 20, 2023
Bronchiectasis, Respiratory disease, Patient, End-user license agreement, Partnership, DPP1, Pharmaceutical industry, Chiesi Farmaceutici

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Key Points: 
  • Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.
  • This agreement expands Chiesi's comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date.
  • Haisco Pharmaceutical will receive an upfront payment and future milestone payments, including royalties on product sales.
  • Under the terms of the agreement, Chiesi will make an upfront payment and additional contingent milestone payments to Haisco, including royalties on product sales.

Chiesi Group signed a License Agreement with Haisco Pharmaceutical to develop, manufacture, and commercialise a novel, reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis

Retrieved on: 
Monday, November 20, 2023
Bronchiectasis, Respiratory disease, Patient, End-user license agreement, Partnership, DPP1, Pharmaceutical industry, Chiesi Farmaceutici

Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.

Key Points: 
  • Chiesi Group and Haisco Pharmaceutical will collaborate closely to develop HSK31858, a novel reversible dipeptidyl peptidase 1 (DPP1) inhibitor for respiratory diseases.
  • This agreement expands Chiesi's comprehensive R&D program in bronchiectasis, a respiratory disease with high unmet medical needs, for which no approved treatment is available to date.
  • Haisco Pharmaceutical will receive an upfront payment and future milestone payments, including royalties on product sales.
  • Under the terms of the agreement, Chiesi will make an upfront payment and additional contingent milestone payments to Haisco, including royalties on product sales.

Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, September 7, 2023
Vamorolone, Marketing, European Medicines Agency, Lead, Prescription Drug User Fee Act, Committee, U.S. FDA, Patient, Committee for Medicinal Products for Human Use, News, Duchenne muscular dystrophy, Glucocorticoid, Becker muscular dystrophy, European Commission, EMA, CEST, PDUFA, Rare, FDA, Safety, Health care, LR, Duchenne, Publication, MAA, MHRA, CHMP, Catalyst Pharmaceuticals, Partnership, European Directive on Traditional Herbal Medicinal Products, NDA, BMD, EC, BST, Medical device, Pharmaceutical industry, Security (finance), Idebenone, EU, Chiesi Farmaceutici, LHON, Atlantic Ocean, Catalysis, DMD

Furthermore, we have secured a solid financial footing which allows us to press ahead toward our goal of European commercialization,” said Dario Eklund, CEO of Santhera.

Key Points: 
  • Furthermore, we have secured a solid financial footing which allows us to press ahead toward our goal of European commercialization,” said Dario Eklund, CEO of Santhera.
  • Total consideration to Santhera is up to USD 231 million (including equity investment) plus royalty payments from product sales.
  • After closing of the transaction in July 2023, Santhera received an upfront payment of USD 90 million (USD 75 million in cash and USD 15 million equity investment).
  • During the six months ending June 30, 2023, Santhera committed to the sale of Raxone/idebenone upon settlement of the French case and the transaction closed on July 28, 2023.

Chiesi Group: Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health

Retrieved on: 
Thursday, September 7, 2023
Exercise, International Day of Clean Air for Blue Skies, Heat, International, Impact, Education, Policy, Health equity, Quality of life, Pollen, Climate change, Element, Facilitation, Patient, Comprehension, Climate, Weather, Health, Prioritise Pleasure, Fossil fuel, Nursing, Personal protective equipment, Chiesi Farmaceutici

Findings reveal poor air quality can act as a barrier to activities that improve patients' quality of life: more than half of patients living in areas with poor air quality avoid outdoor exercise and social engagement.

Key Points: 
  • Findings reveal poor air quality can act as a barrier to activities that improve patients' quality of life: more than half of patients living in areas with poor air quality avoid outdoor exercise and social engagement.
  • By focusing on those suffering from the health impacts of the climate crisis, Chiesi wants to help prevent this major health threat and promote understanding and collaboration between sustainability and health experts.
  • "Policymakers must consider that both climate-related and socio-economic factors interplay and can have an impact on patients' health and quality of life.
  • Cleaner air, clearer lungs, better lives: exploring the intersection of air quality, health inequalities and lung health.

Chiesi Group: Climate Change Threatens Respiratory Patients' Quality of Life Stretching Beyond Physical Health

Retrieved on: 
Thursday, September 7, 2023
Exercise, International Day of Clean Air for Blue Skies, Heat, International, Impact, Education, Policy, Health equity, Quality of life, Pollen, Climate change, Element, Facilitation, Patient, Comprehension, Climate, Weather, Health, Prioritise Pleasure, Fossil fuel, Nursing, Personal protective equipment, Chiesi Farmaceutici

Findings reveal poor air quality can act as a barrier to activities that improve patients' quality of life: more than half of patients living in areas with poor air quality avoid outdoor exercise and social engagement.

Key Points: 
  • Findings reveal poor air quality can act as a barrier to activities that improve patients' quality of life: more than half of patients living in areas with poor air quality avoid outdoor exercise and social engagement.
  • By focusing on those suffering from the health impacts of the climate crisis, Chiesi wants to help prevent this major health threat and promote understanding and collaboration between sustainability and health experts.
  • "Policymakers must consider that both climate-related and socio-economic factors interplay and can have an impact on patients' health and quality of life.
  • Cleaner air, clearer lungs, better lives: exploring the intersection of air quality, health inequalities and lung health.

Fabry Disease Industry Insights 2023-2032: Epidemiology, Drug Pipeline, Emerging Treatments, Market Trends, Expert Opinions - ResearchAndMarkets.com

Retrieved on: 
Friday, August 25, 2023
Health, Other Health, EU4, Subject-matter expert, Chiesi Farmaceutici, Internet, USD, AAV, Protalix BioTherapeutics, ERT, GLA, Sangamo Therapeutics, Growth, Late onset congenital adrenal hyperplasia, Classic, Enzyme replacement therapy, Epidemiology, PEGylation, SME, Pharmaceutical industry, Vaccine, Video game, Dentistry, Fabry, EU, Fabry disease

This comprehensive analysis offers valuable insights into the Fabry Disease market, including epidemiology, drug pipeline, emerging treatments, market trends, and expert opinions, ultimately assisting stakeholders in understanding the evolving landscape and potential opportunities.

Key Points: 
  • This comprehensive analysis offers valuable insights into the Fabry Disease market, including epidemiology, drug pipeline, emerging treatments, market trends, and expert opinions, ultimately assisting stakeholders in understanding the evolving landscape and potential opportunities.
  • The report provides a comprehensive understanding of Fabry Disease epidemiology, including historical and forecasted data.
  • The Fabry Disease market experienced 15,290 diagnosed prevalent cases in the 7MM in 2022, with 8,355 cases in the US alone.
  • The Fabry Disease market size is projected to increase at a CAGR of 6.3% from 2023 to 2032, driven by awareness and the launch of emerging drugs.

Chiesi Global Rare Diseases Announces Co-Development Agreement with Aliada Therapeutics to Advance Blood-Brain Barrier-Crossing Platform Technology in Lysosomal Storage Disorders

Retrieved on: 
Tuesday, August 15, 2023
Central nervous system, Drug development, Therapy, MODEL, DSM-IV codes, Hope, Traffic barrier, Brain, Research, LSD, CNS, BBB, Patient, Rare, FDA, Glycogen storage disease, Pharmaceutical industry, Medical device, Chiesi Farmaceutici, 2-Bromo-LSD

BOSTON, Aug. 15, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people living with rare diseases, today announced a co-development agreement with Aliada Therapeutics, a biotechnology company developing a novel blood-brain barrier (BBB)-crossing platform technology to address challenging disease areas with high unmet need.

Key Points: 
  • "Our commitment to the development of new treatment options for people living with lysosomal storage disorders (LSD) is global, as evidenced by recent regulatory approvals," said Giacomo Chiesi, head of Chiesi Global Rare Diseases.
  • We are especially proud to advance this important research with Aliada, a partner with vast experience in neuro drug development and biologics delivery."
  • Founded in 2021, Aliada leverages its MODEL platform to research and develop differentiated large molecule therapeutics for patients with neurological disorders and systemic disorders with CNS involvement.
  • This collaboration will allow Aliada to demonstrate the diverse capabilities of our MODEL platform, which enables us to efficiently transport a diverse range of therapeutic cargoes into the brain."

Chiesi Group Mid-Year Financial Results Demonstrate Strong Growth for 2023

Retrieved on: 
Tuesday, August 8, 2023
Benefit corporation, Social conditions in Honduras, Research, Science, Acquisition, CARE, Patient, AIR, Growth, RARE, Pharmaceutical industry, Chiesi Farmaceutici

(key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Chiesi Group is continuing to experience major growth this year.

Key Points: 
  • (key-A-zee), a Cary-based specialty pharmaceutical company, announced today that Chiesi Group is continuing to experience major growth this year.
  • The Group’s 2023 sales for the first half of the year are at €1,497 million, representing growth of 12% compared with 2022.
  • Chiesi USA, is the U.S. affiliate of Chiesi Farmaceutici, an international research-focused pharmaceutical group based in Parma, Italy with 31 affiliates worldwide.
  • In 2023, the Group anticipates revenues of about €3 billion with projected further growth in 2024.